<DOC>
	<DOCNO>NCT02118727</DOCNO>
	<brief_summary>The purpose study determine memantine 20 mg BID use conjunction riluzole , slow disease progression patient ALS include potentially improve neuropsychiatric change , well determine CSF protein biomarkers use diagnostic prognostic marker patient ALS . Funding Source-FDA OOPD</brief_summary>
	<brief_title>Therapy Amyotrophic Lateral Sclerosis With Memantine 20 mg BID ( TAME )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) fatal neurodegenerative disease affect 30,000 Americans year . Of 30,000 Americans , suggest 50 % experience cognitive behavioral change form frontotemporal dysfunction 40 % meet criterion frontotemporal dementia ( FTD ) . Riluzole FDA approve agent ALS extend patient 's lifespan 2-3 month , proven therapy cognitive change associate ALS . More effective therapy universally fatal disease desperately need . Results open label pilot trial 20 patient treat memantine 10 mg BID suggest treatment combination memantine riluzole slow ALS disease progression . This trial also show level specific protein biomarkers CSF baseline correlate rate disease progression . A concurrent phase II study perform Dr Carvalho , find effect similar dosing ; however , study limit term power . Comments previous fail drug trial ALS raise concern many ALS trial study potential therapeutic agent single dose thus may miss potential efficacy non FDA approve dos ; therefore , propose study test high dose memantine , 20 mg BID , double blind , placebo control , randomize trial 90 patient ALS determine combination therapy memantine riluzole slow disease progression compare treatment riluzole alone . The primary outcome measure rate disease progression measure ALS Functional Rating Scale- Revised ( ALSFRS-R ) . In addition investigator examine cognitive deficit see ALS patient measure ALS Cognitive Behavioral Screen ( ALS-CBS ) Neuropsychiatric Inventory Questionnaire ( NIP-Q ) . Finally investigator examine specific validate protein biomarkers find cerebrospinal fluid determine correlation level biomarkers rate disease progression . In particular investigator measure ratio phosphorylated heavy neurofilament Complement 3 see ratio predictive disease progression level change therapy memantine . This project offer unique insight untreatable disease . If study confirms earlier result suggest memantine , use conjunction riluzole , significantly slow progression disease , well ameliorate cognitive deficit patient fronto-temporal dysfunction , set groundwork conduct large phase III trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Age 1885 2 . Male Female 3 . Clinically definite probable ALS El Escorial criterion 4 . ALSFRS &gt; 25 5 . On stable dose Rilutek 50 mg bid least 30 day prior screen 6 . Capable provide informed consent comply trial procedure 1 . Patients FVC 60 % 2 . History liver disease 3 . Severe renal failure 4 . History intolerance Riluzole memantine 5 . Evidence motor neuron disease great 3 year 6 . Any comorbid condition would make completion trial unlikely 7 . If female , pregnant breastfeeding ; , childbearing age , unwillingness use birth control . 8 . Taking trial medication . Nontrial medication cause exclusion . 9 . Unwillingness provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ALS</keyword>
	<keyword>FTD</keyword>
	<keyword>Tau</keyword>
	<keyword>pNF-H/C3</keyword>
</DOC>